Center-Authored Papers

Filters: Author is Fisher, Richard I  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, Francis CW.  2006.  Venous thromboembolism in patients with diffuse large B-cell lymphoma.. Leukemia & lymphoma. 47(6):1029-33. Abstract
U
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES et al..  2016.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(17):2020-+. Abstract
T
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH.  2006.  Thromboembolism in hospitalized neutropenic cancer patients.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(3):484-90. Abstract
S
Moinpour CM, Unger JM, Ganz PA, Kornblith AB, Gaynor ER, Bowers MA, Gatti GS, Kaminski MS, Erba HP, Wang T et al..  2016.  Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.. Journal of cancer survivorship : research and practice. Abstract
R
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, LeBlanc M, Maloney DG, Press OW, Miller TP, Rimsza LM.  2012.  Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45. Haematologica. 97(11):e46.
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA et al..  2016.  RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. British journal of haematology. Abstract
Friedberg JW, Unger JM, Burack RW, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP et al..  2014.  R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.. British journal of haematology. Abstract
P
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI.  2008.  Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.. Transplantation. 86(2):215-22. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20. Abstract
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.  2012.  A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.. Blood. Abstract
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox A-M et al..  2016.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.. Leukemia & lymphoma. 57(10):2359-2369. Abstract
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP.  2012.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.. Cancer. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract
N
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.  2005.  New treatment options have changed the survival of patients with follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(33):8447-52. Abstract
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE et al..  2016.  NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(9):1067-79. Abstract
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Caimi P, Fayad LE et al..  2017.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3):293-311. Abstract
Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI.  2009.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(1):114-9. Abstract